A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3 + regulatory ...

—Michael J. Mauro, MD, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, at Memorial Sloan Kettering Cancer Center, discusses the current understanding of TKI discontinuation and ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

Two posters presented at the European Hematology Association 2021 Virtual Congress evaluated tyrosine kinase inhibitor (TKI) selection in the front line and compared first-generation to ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib ...